The world’s largest drugmaker, Eli Lilly & Co., just notched another milestone: it’s the first health-care company to cross the $1 trillion threshold as investors bet big on the drugmaker’s ...

The 150-year-old drugmaker is the first company in health care to hit the milestone. By Rebecca Robbins Eli Lilly, the maker of hugely popular weight loss drugs, has reached $1 trillion in value, ...

Silicon Valley’s giants crowd the list of the world’s most valuable companies, but drugmaker Eli Lilly is hot on their heels. The company topped a market capitalization of $1 trillion on Friday, ...

Anthony Mason is a senior culture and senior national correspondent for CBS News. He has been a frequent contributor to "CBS Sunday Morning." Vice President of Growth & Engagement at CBS News and ...

The authors do not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and have disclosed no relevant affiliations beyond their ...

Eli Lilly has linked its amylin agonist eloralintide to up to 20.1% weight loss at Week 48, encouraging the drugmaker to prepare to enter phase 3 next month. Lilly showed it is a contender for the ...

Early results showed that patients lost up to 20.1% of their body weight. Eli Lilly's next generation of weight loss drugs appear to show promise, possibly leading to even faster weight loss and added ...

Lily Allen’s new album, West End Girl, has pulled the rug out from under happily-married-after dreams. The record is an odyssey of betrayal and heartbreak, an investigation of the way we perceive ...

Daniel Payne reports on how the health industry and Washington influence and impact each other. He joined STAT in 2025 after covering health care at POLITICO. You can reach Daniel on Signal at danielp ...

Eli Lilly is dominating the large and rapidly growing incretin analog market in the U.S. with its GLP-1 drug, tirzepatide. Its investigational oral GLP-1 drug, orforglipron, could significantly expand ...

Elaine Gregersen does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...